From Molecule to Market: Simplifying the Characterization of Antibody-Drug Conjugates (ADCs)

Antibody-drug conjugates (ADCs) are among the fastest growing class of biologics and are developed as a combination of monoclonal antibodies (mAbs) and highly potent cytotoxic molecules (drugs). The antibody, in addition to its own biological specificity through its paratope, has the function of a targeted transporting tool of the drug to the targeted cell. The conjugated molecules or particles typically have cytotoxic activity and thus increase the efficiency of the antibody by an additional mechanism, leading to increased death of cells carrying the target antigen.

Conjugation of these drugs to antibodies, however, increases structural complexity which triggers the need for improved characterization methods. Common analytical technologies for characterization of ADCs, such as liquid chromatography, electrophoresis, and mass spectrometry, are useful in enabling the optimization of ADCs but need to be complemented with technologies that can add biophysical and functional information.

This webinar will demonstrate the use of Octet® bio-layer interferometry (BLI) platform in combination with the iQue® Advanced Flow Cytometry Platform to characterize and compare the drug trastuzumab to the trastuzumab-containing reference medicinal products Kadcyla® and Enhertu®.